羟吗啡酮
耐受性
药代动力学
医学
药理学
生物等效性
麻醉
不利影响
内科学
类阿片
羟考酮
受体
作者
Paul Gavin,Lee S. Simon,Thomas G. Schlagheck,Alisha J Smith,Janakan Krishnarajah
出处
期刊:Pain management
[Future Medicine]
日期:2017-11-01
卷期号:7 (6): 499-512
被引量:1
标识
DOI:10.2217/pmt-2017-0032
摘要
Aim: Characterize the pharmacokinetic profile and tolerability of two tocopheryl phosphate mixture/oxymorphone patch formulations in healthy subjects, and the active metabolite (6-OH-oxymorphone). Materials & methods: Fifteen participants received a single application of oxymorphone patches +/− capsaicin for 72 h and were crossed-over for another 72 h. Results: Plasma oxymorphone was detected approximately 7 h and 6-OH-oxymorphone after approximately 18–19 h postapplication of both formulations, respectively. For oxymorphone, median t max was 24 h, and C max /C min ratio was approximately 2.4. The most frequently reported treatment-related adverse event was application site reaction, mainly with capsaicin formulation. Conclusion: Tocopheryl phosphate mixture/oxymorphone transdermal patches can successfully deliver therapeutic amounts of oxymorphone in a sustained manner over 72 h and are well tolerated. ANZCTR registration number: ACTRN12614000613606
科研通智能强力驱动
Strongly Powered by AbleSci AI